Security Snapshot

Arcutis Biotherapeutics, Inc. - COMMON STOCK (ARQT) Institutional Ownership

CUSIP: 03969K108

13F Institutional Holders and Ownership History from Q1 2020 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

155

Shares (Excl. Options)

46.63MFull value: 46,634,756 · shares · 30 Sep 2026

Price

$26.43

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / COMMON STOCK
Symbol
ARQT on Nasdaq
All holders as of 30 Sep 2026
Q3 2026
Total 13F shares
46,634,756
Latest holder snapshot 5 signals
Total 13F value
$1,247,668,052
Portfolio coverage rank
0%
Share change
+5,525,036
Value change
+$146,782,028
Number of holders
155
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
126,534,885
SEC-reported price per share
$26.43
Insider filing price
$26.43
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ARQT - Arcutis Biotherapeutics, Inc. - COMMON STOCK is tracked under CUSIP 03969K108.
  • 155 institutions reported positions in Q3 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 273 to 155 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $3.45BFull value: $3,446,408,572 · USD · 30 Jun 2026
    to
    $1.25BFull value: $1,247,668,052 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 155 institutions filings for Q3 2026.

Open SEC evidence

Security key

03969K108

13F reference period

Q3 2026

13F holders

155

13D/G owners

7

CIK / CUSIP context first

Open Q3 2026 holders ARQT full holder history Arcutis Biotherapeutics, Inc. SEC filings Arcutis Biotherapeutics, Inc. company facts Arcutis Biotherapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
ARQT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14% $423,371,725 17,751,435 BlackRock, Inc. 30 Sep 2026
Frazier Life Sciences VIII, L.P. 7.5% $130,399,321 8,943,712 Patrick J. Heron 18 Aug 2025
Rubric Capital Management LP 6.8% $239,875,733 8,271,577 Rubric Capital Management LP 31 Dec 2025
STATE STREET CORP 6.1% +28% $204,003,338 +$50,105,677 7,718,628 +33% STATE STREET CORPORATION 30 Sep 2026
Polar Capital Holdings Plc 5.3% +27% $173,234,098 +$41,964,402 6,606,945 +32% Polar Capital Holdings Plc 30 Jun 2026
PRUDENTIAL FINANCIAL INC 4.3% -23% $127,901,438 -$42,866,378 5,302,713 -25% PRUDENTIAL FINANCIAL INC 31 Mar 2026
JENNISON ASSOCIATES LLC 4% -25% $120,136,172 -$42,866,932 4,980,770 -26% Jennison Associates LLC 31 Mar 2026
As of 30 Sep 2026, 155 institutional investors reported holding
46.63MFull value: 46,634,756 · shares · 30 Sep 2026
shares of Arcutis Biotherapeutics, Inc. - COMMON STOCK (ARQT). This represents 37% of the company’s total
126.53MFull value: 126,534,885 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
33%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
STATE STREET CORP 6.1% 7,718,628 +33% 0.01% $204,003,338
MORGAN STANLEY 4.2% 5,296,532 +19% 0.01% $139,987,355
VANGUARD CAPITAL MANAGEMENT LLC 3.9% 4,994,043 +0.11% 0% $131,992,556
VANGUARD PORTFOLIO MANAGEMENT LLC 3% 3,817,697 +57% 0% $100,901,732
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,970,720 -0.39% 0% $78,530,844
FRANKLIN TEMPLETON INC 1.6% 1,978,286 +2.4% 0.01% $67,360,639
AMERICAN CENTURY COMPANIES INC 1.6% 1,975,939 +2.6% 0.02% $52,224,125
Aberdeen Group plc 0.95% 1,204,900 +9.7% 0.04% $31,845,507
FEDERATED HERMES, INC. 0.92% 1,165,662 +3.6% 0.04% $30,808,447
Pivotal bioVenture Partners Investment Advisor LLC 0.8% 1,008,174 -20% 11% $26,646,039
Candriam S.C.A. 0.79% 1,003,729 +5.7% 0.12% $26,625,484
Perpetual Ltd 0.76% 958,843 -14% 0.39% $25,342,221
Simplify Asset Management Inc. 0.68% 865,862 0.39% $22,884,733
VANGUARD FIDUCIARY TRUST CO 0.64% 814,480 -0.08% 0% $21,526,706
MANUFACTURERS LIFE INSURANCE COMPANY, THE 0.64% 813,893 +0.26% 0.02% $21,511,192
Public Sector Pension Investment Board 0.61% 774,309 0.04% $20,325,611
JUPITER ASSET MANAGEMENT LTD 0.56% 709,620 +250% 0.09% $18,755,257
FISHMAN JAY A LTD/MI 0.47% 597,115 1.3% $15,781,749
Qube Research & Technologies Ltd 0.39% 493,269 +36% 0.01% $13,037,100
RENAISSANCE TECHNOLOGIES LLC 0.38% 476,099 +715% 0.02% $12,583,297
CAPITOLIS LIQUID GLOBAL MARKETS LLC 0.36% 459,100 -8.2% 0.05% $12,134,013
DEUTSCHE BANK AG\ 0.36% 450,999 +18% 0% $11,919,904
Invesco Ltd. 0.33% 416,331 +57% 0% $11,003,628
PEREGRINE CAPITAL MANAGEMENT LLC 0.29% 361,431 +24% 0.32% $9,552,621
Privium Fund Management B.V. 0.26% 333,193 -17% 1.7% $8,806,291

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
27
Headline period
Q3 2026
Rows shown
1-25 of 27
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 46,634,756 $1,247,668,052 +$146,782,028 $26.43 155
2026 Q2 131,439,955 $3,446,408,572 +$1,382,019 $26.22 273
2026 Q1 132,368,934 $3,118,364,705 +$52,314,750 $23.56 269
2025 Q4 128,962,296 $3,744,475,286 +$103,845,955 $29.04 280
2025 Q3 125,804,940 $2,370,184,094 -$12,772,142 $18.85 235
2025 Q2 127,080,415 $1,781,069,063 +$21,637,125 $14.02 228
2025 Q1 125,020,441 $1,954,466,256 -$63,284,061 $15.64 239
2024 Q4 128,710,441 $1,792,934,402 +$13,789,213 $13.93 206
2024 Q3 128,641,664 $1,198,282,493 +$15,921,001 $9.30 187
2024 Q2 126,503,507 $1,176,619,915 +$9,242,287 $9.30 184
2024 Q1 124,986,945 $1,238,517,575 +$285,414,998 $9.91 166
2023 Q4 101,272,913 $327,119,655 +$79,248,549 $3.23 130
2023 Q3 67,159,664 $356,705,615 -$26,597,323 $5.31 131
2023 Q2 71,766,867 $683,988,878 -$5,745,956 $9.53 135
2023 Q1 71,600,840 $787,595,702 +$44,255,428 $11.00 141
2022 Q4 65,632,382 $971,340,873 +$87,400,990 $14.80 138
2022 Q3 59,389,299 $1,134,920,691 +$194,978,652 $19.11 138
2022 Q2 49,075,739 $1,045,833,934 +$17,642,019 $21.31 112
2022 Q1 48,307,139 $929,780,885 -$136,426,148 $19.26 106
2021 Q4 46,348,278 $961,255,152 -$1,852,441 $20.74 89
2021 Q3 45,697,453 $1,091,410,573 +$4,816,184 $23.89 103
2021 Q2 45,474,760 $1,240,848,739 -$38,040,013 $27.29 100
2021 Q1 46,841,365 $1,354,985,371 +$170,660,745 $28.93 93
2020 Q4 40,973,719 $1,152,598,120 +$138,537,380 $28.13 78
2020 Q3 34,766,158 $1,018,651,387 +$28,894,471 $29.30 62
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .